PMID- 28947024
OWN - NLM
STAT- MEDLINE
DCOM- 20180604
LR  - 20181202
IS  - 1532-3064 (Electronic)
IS  - 0954-6111 (Linking)
VI  - 131
DP  - 2017 Oct
TI  - Real-life effectiveness of asthma treatment with a fixed-dose 
      fluticasone/formoterol pressurised metered-dose inhaler - Results from a 
      non-interventional study.
PG  - 166-174
LID - S0954-6111(17)30287-1 [pii]
LID - 10.1016/j.rmed.2017.08.017 [doi]
AB  - OBJECTIVE: Prospective, non-interventional study of fixed-dose inhaled 
      corticosteroid (ICS)/long-acting beta(2)-agonist (LABA) combination therapy with 
      fluticasone propionate/formoterol fumarate (FP/FORM) across a spectrum of 
      community-based patients with asthma in a real-life setting. METHODS: In 
      FP/FORM-treated patients aged >/=12 years, asthma control (Asthma Control Test 
      [ACT]), incidence of severe exacerbations, lung function, quality of life (asthma 
      quality of life questionnaire [AQLQ]) and adverse events (AEs) were assessed over 
      one year. RESULTS: Almost 40% (n = 555) of the full analysis population 
      (N = 1410) were receiving ICS/LABA therapy prior to enrolment; 69.8% completed 
      the study. Asthma control (mean ACT +/- standard deviation) improved from 
      16.3 +/- 5.0 at baseline to 19.8 +/- 4.5 at study end. ACT scores were significantly 
      (p < 0.0001) higher than baseline at all observation timepoints, including the 
      first assessment at 4-6 weeks. The percentage of patients with asthma control 
      increased (baseline: 30.9%; study end: 62.4%), and the percentage of patients 
      with >/=1 severe asthma exacerbation decreased (12 months before: 35.8%; during 
      study: 5.9%). Lung function (forced expiratory volume in one second, peak 
      expiratory flow) improved from baseline to each observation timepoint (p < 0.0001 
      for all). Improvement in asthma status was accompanied by ameliorated quality of 
      life: AQLQ scores improved significantly from baseline to all observation 
      timepoints (p < 0.0001 for all). AEs accorded with the summary of product 
      characteristics. After study completion, 70% of patients continued FP/FORM 
      treatment. CONCLUSION: In this one-year study, FP/FORM treatment was associated 
      with clinically relevant improvements in asthma status in a diverse population of 
      patients under real-life conditions.
CI  - Copyright (c) 2017. Published by Elsevier Ltd.
FAU - Schmidt, O
AU  - Schmidt O
AD  - Pneumologische Gemeinschaftspraxis, Emil-Schuller-Str. 29, Koblenz, Germany.
FAU - Petro, W
AU  - Petro W
AD  - Medizinisches Versorgungszentrum (MVZ) Bad Reichenhall im Gesundheitszentrum 
      Salus, Rinckstr. 7-9, Bad Reichenhall, Germany.
FAU - Hoheisel, G
AU  - Hoheisel G
AD  - Praxis fur Pneumologie und Allergologie, August-Bebel-Str. 69, Leipzig, Germany.
FAU - Kanniess, F
AU  - Kanniess F
AD  - Gemeinschaftspraxis Reinfeld, Praxis fur Allgemeinmedizin und Allergologie, 
      Bahnhofstrasse 5a, Reinfeld, Germany.
FAU - Oepen, P
AU  - Oepen P
AD  - Mundipharma GmbH, Mundipharmastrasse 2, Limburg (Lahn), Germany.
FAU - Langer-Brauburger, B
AU  - Langer-Brauburger B
AD  - Mundipharma GmbH, Mundipharmastrasse 2, Limburg (Lahn), Germany. Electronic 
      address: Birgit.Langer-Brauburger@mundipharma.de.
LA  - eng
PT  - Journal Article
DEP - 20170819
PL  - England
TA  - Respir Med
JT  - Respiratory medicine
JID - 8908438
RN  - 0 (Androstadienes)
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Drug Combinations)
RN  - 0 (Ethanolamines)
RN  - 0 (fluticasone-formoterol)
RN  - CUT2W21N7U (Fluticasone)
RN  - W34SHF8J2K (Formoterol Fumarate)
SB  - IM
MH  - Administration, Inhalation
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Androstadienes/*therapeutic use
MH  - Anti-Asthmatic Agents/*therapeutic use
MH  - Asthma/*drug therapy
MH  - Child
MH  - Disease Progression
MH  - Drug Combinations
MH  - Ethanolamines/*therapeutic use
MH  - Female
MH  - Fluticasone
MH  - Formoterol Fumarate
MH  - Humans
MH  - Male
MH  - *Metered Dose Inhalers
MH  - Middle Aged
MH  - Prospective Studies
MH  - Quality of Life
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - Asthma control
OT  - Fixed combination
OT  - Fluticasone
OT  - Formoterol
OT  - Non-interventional
OT  - Quality of life
EDAT- 2017/09/28 06:00
MHDA- 2018/06/05 06:00
CRDT- 2017/09/27 06:00
PHST- 2017/01/26 00:00 [received]
PHST- 2017/08/17 00:00 [revised]
PHST- 2017/08/17 00:00 [accepted]
PHST- 2017/09/27 06:00 [entrez]
PHST- 2017/09/28 06:00 [pubmed]
PHST- 2018/06/05 06:00 [medline]
AID - S0954-6111(17)30287-1 [pii]
AID - 10.1016/j.rmed.2017.08.017 [doi]
PST - ppublish
SO  - Respir Med. 2017 Oct;131:166-174. doi: 10.1016/j.rmed.2017.08.017. Epub 2017 Aug 
      19.